HK1206246A1 - Use of high dose laquinimod for treating multiple sclerosis (laquinimod) - Google Patents

Use of high dose laquinimod for treating multiple sclerosis (laquinimod)

Info

Publication number
HK1206246A1
HK1206246A1 HK15106789.5A HK15106789A HK1206246A1 HK 1206246 A1 HK1206246 A1 HK 1206246A1 HK 15106789 A HK15106789 A HK 15106789A HK 1206246 A1 HK1206246 A1 HK 1206246A1
Authority
HK
Hong Kong
Prior art keywords
laquinimod
multiple sclerosis
high dose
treating multiple
treating
Prior art date
Application number
HK15106789.5A
Other languages
English (en)
Chinese (zh)
Inventor
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206246(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1206246A1 publication Critical patent/HK1206246A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15106789.5A 2012-05-02 2015-07-16 Use of high dose laquinimod for treating multiple sclerosis (laquinimod) HK1206246A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02
PCT/US2013/039090 WO2013166166A1 (en) 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
HK1206246A1 true HK1206246A1 (en) 2016-01-08

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106789.5A HK1206246A1 (en) 2012-05-02 2015-07-16 Use of high dose laquinimod for treating multiple sclerosis (laquinimod)

Country Status (21)

Country Link
US (3) US20130303569A1 (es)
EP (1) EP2844255A4 (es)
JP (2) JP2015515985A (es)
KR (1) KR20150013658A (es)
CN (2) CN104284663A (es)
AR (1) AR090885A1 (es)
AU (1) AU2013256352A1 (es)
BR (1) BR112014027010A2 (es)
CA (1) CA2870684A1 (es)
CL (1) CL2014002935A1 (es)
EA (1) EA201492010A1 (es)
HK (1) HK1206246A1 (es)
IL (1) IL235337A0 (es)
MX (1) MX2014013039A (es)
PE (1) PE20150161A1 (es)
PH (1) PH12014502447A1 (es)
SG (1) SG11201406594UA (es)
TW (2) TW201347762A (es)
UY (1) UY34775A (es)
WO (1) WO2013166166A1 (es)
ZA (1) ZA201408820B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140101333A (ko) 2011-10-12 2014-08-19 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료
TW201345527A (zh) 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗-TNFα療法無效之克隆氏症患者之用途
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
EP2961406A4 (en) * 2012-10-12 2017-01-04 Teva Pharmaceutical Industries Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
US8975279B2 (en) 2012-11-07 2015-03-10 Teva Pharmaceutical Industries, Ltd. Amine salts of laquinimod
MX2015010296A (es) * 2013-02-15 2016-05-05 Teva Pharma Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
KR20150143499A (ko) 2013-03-14 2015-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
KR20210034623A (ko) * 2018-07-20 2021-03-30 메르크 파텐트 게엠베하 다발성 경화증의 치료 및 예방을 위한 방법에서 사용하기 위한 치환된 아미노-피리미딘 화합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
KR20140101333A (ko) * 2011-10-12 2014-08-19 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료
MX2015010296A (es) * 2013-02-15 2016-05-05 Teva Pharma Tratamiento de formas progresivas de esclerosis multiple con laquinimod.

Also Published As

Publication number Publication date
PE20150161A1 (es) 2015-02-22
UY34775A (es) 2013-11-29
US20130303569A1 (en) 2013-11-14
EP2844255A4 (en) 2015-10-14
PH12014502447A1 (en) 2015-01-12
ZA201408820B (en) 2016-06-29
US20150265592A1 (en) 2015-09-24
WO2013166166A1 (en) 2013-11-07
JP2015515985A (ja) 2015-06-04
AR090885A1 (es) 2014-12-10
JP2017222691A (ja) 2017-12-21
BR112014027010A2 (pt) 2017-06-27
SG11201406594UA (en) 2014-11-27
CL2014002935A1 (es) 2015-03-06
IL235337A0 (en) 2014-12-31
AU2013256352A1 (en) 2014-11-27
EA201492010A1 (ru) 2015-06-30
TW201804997A (zh) 2018-02-16
TW201347762A (zh) 2013-12-01
US20160000775A1 (en) 2016-01-07
KR20150013658A (ko) 2015-02-05
EP2844255A1 (en) 2015-03-11
CA2870684A1 (en) 2013-11-07
CN104284663A (zh) 2015-01-14
CN105832733A (zh) 2016-08-10
MX2014013039A (es) 2015-02-04

Similar Documents

Publication Publication Date Title
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis (laquinimod)
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
HK1206937A1 (en) Methods of administering pirfenidone therapy
PT2857019T (pt) Método de tratamento de esclerose múltipla
IL234813A0 (en) Methods for increasing the efficacy of cd37-based therapy
SI2812013T1 (sl) Formulacija za zdravljenje SRČ-ja
PL3524260T3 (pl) Kompozycje farmaceutyczne do leczenia braku apetytu
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
HUE044796T2 (hu) Gyógyászati készítmény hiperkoleszterinémia kezelésére
EP2897607A4 (en) BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER
IL236718A (en) Vegfr-3 inhibitors for the preparation of drugs for the treatment of liver carcinoma
IL244620A0 (en) A drug combination including laquinimod for the treatment of multiple sclerosis
HK1206633A1 (en) Composition for treatment of warts
EP2800763A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
HUE039044T2 (hu) Gyógyászati kompozíció sclerosis multiplex kezelésére
IL228464A (en) Quinolone analogues for use in the preparation of MS drugs